ArticlePloS one2025
Moringa oleifera potential for the treatment and prevention of COVID-19 involving molecular interaction, antioxidant properties and kinetic mechanism.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond Antioxidant Activity: Redox-Inflammatory Network Modulation as a Framework for the Multi-Organ Pharmacology ofJournal of experimental pharmacology · 2026Review
- From bench to bedside: experimental pharmacology approaches to overcome bioavailability, stability, and translational barriers of bioactive peptides from natural sources.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic, caused by the emergence of the SARS-CoV-2 virus in 2019, has led to a global state of emergency declared by the World Health Organization (WHO). The search for effective therapies against the virus is ongoing, and traditional medicine is emerging as a promising alternative, as many plants with known antiviral potential have been utilized during the pandemic. In this study, we investigated the inhibition of cysteine proteases (Mpro, PLpro, and papain) by bioactive compounds from Moringa oleifera leaves, with the ultimate goal of developing a novel treatment. We conducted a virtual screening based on the structure of the Mpro and PLpro enzymatic targets of SARS-CoV-2, for the selection of compounds with higher inhibitory potential. We then identified 14 bioactive compounds with high binding energy against Mpro and PLpro using AutoDock. Gamma-sitosterol was particularly promising since it showed higher interaction energy with Mpro (-8.6Kcal/mol) and PLpro (-7.4Kcal/mol). Phytochemicals in Moringa oleifera leaves were extracted using aqueous and hydromethanolic solvent system. It was found that polyphenols (4.20-5.01 mg GAE/g DM) and flavonoids (95.86-135.41 mg QE/ g DM) were the major constituents in the extracts. Antioxidant activity in the extracts, particularly DPPH scavenging activity (63.46-123.58 mg TE/g DM) and FRAP activity (48.14-49.66 mg TE/g DM), was high suggesting a potential for the prevention of oxidation and inflammation. Global and multiple alignment were conducted between Mpro, PLpro and papain, and results showed high conservation of the amino acid residues in the active site of the enzymes, suggesting a similar molecular catalysis mechanism. The extracts showed inhibitory activity against papain with the IC50 of 7.5 mg/mL for the hydromethanolic extract and 12.5 mg/mL for the aqueous extract. It was found in kinetic studies that hydromethanolic extract was a competitive inhibitor of papain, while aqueous extract was a hyperbolic non-competitive inhibitor, suggesting the presence of compounds with different interaction profiles to the enzymes. This study demonstrates that Moringa oleifera leaf extracts have substantial antioxidant activity and inhibit the model cysteine protease papain in vitro. These data, together with in silico docking against Mpro and PLpro, identify candidate phytochemicals that merit further evaluation; however, papain inhibition is a preliminary biochemical filter and does not by itself establish antiviral activity against SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.